Browsing Tag
inflammatory bowel disease
16 posts
Can Eli Lilly and Company’s Omvoh reset expectations for long-term Crohn’s disease control?
Three-year Omvoh data shows durable steroid-free remission in Crohn’s disease. Read how this reshapes Eli Lilly and Company’s long-term strategy.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.
Eli Lilly acquires Organovo’s FXR program to advance IBD drug development
In a significant industry development, Eli Lilly and Company has acquired Organovo Holdings, Inc.’s FXR program, including its…
Ensho Therapeutics unveils new data on NSHO-101 as once-daily treatment for inflammatory bowel disease
Ensho Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing oral therapies for inflammatory diseases, has presented promising…
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial,…
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics,…
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal,…
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated…
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion,…
Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment
Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising…